How it works

Patented technology

The tragedy of diabetic retinopathy is that in the vast majority of cases, blindness is preventable by early diagnosis and treatment. Fundus image analysis present several challenges, which have been addressed in the invention of the RetinaLyze software. Automatic extraction and analysis of the vascular tree is an important task in fundus image analysis, since the vascular tree is the most prominent feature of the retina and it is present regardless of health condition. It is important to be able to make screenings frequently since diabetes is the primary reason for blindness among working age adults. It is a disease that, among its many symptoms, includes a progressive impairment of the peripheral vascular system. These changes in the vasculature of the retina cause progressive vision impairment and eventually complete loss of eyesight.

The RetinaLyze system is a vector-based algoritm and the patented invention relates to a method for assessing the presence or absence of retinal lesion(s) in an image. The RetinaLyze screening is an analysis performed on a Fundus Photo. The Fundus Photo is taken with a non-mydriatic Fundus Camera, connected to a digital system, which can store the digital images and upload them to the web application.

Screenshot 1
Screenshot 2

 

The images are analysed by the RetinaLyze web application. In 85-90% of the cases no leasions will be detected, and the optometrist can store the image and ask the patient to return next year for a new test. In the event of lesions the image must be sent to a specialist, who will provide the optometrist with the answer to the patient. In some cases the patient will be advised to contact an opthalmologist for further procedures.

For questions or further info please contact us.

Requirements

Equipment

  • Digital non-mydriatic funduscamera. The higher the resolution, the better.
  • A PC with storage space.
  • Internet access

Installation

  • RetinaLyze is a webbased application.
  • We can perform a short setup and intro if wished.

Potential users

  • Optometrists
  • Opthalmogists staff
  • Ophthalmologists
  • Diabetes clinic staff

Types of analysis

RetinaLyze DR

One of the most feared consequences of diabetes is retinal diabetic pathology, since this can lead to blindness. Early diagnosis is crucial – and possible with RetinaLyze DR. RetinaLyze DR is made to focus on detecting the early signs of Diabetic Retinopathy. Learn more about Diabetic Retinopathy in the video below.

RetinaLyze AMD

Is designed to find white lesions on the Retina. Like RetinaLyze DR, RetinaLyze AMD is made to find the early sign of Age-related Macular Degenerations or the initial stages of the AMD process, which can occur in the eye. Since the programme is made to find the early signs of AMD, it focuses on white lesions on the retina (Dry nonexudative AMD).  Learn more about AMD in the video below.

Looking for documentation?

CE

RetinaLyze has been scientifically tested and CE-marked according to Medical Device Directive 93/42/EEC from the 14th of June 1993 and Declaration 1263 from December 2008.